Role of aspirin with thrombolytic therapy in acute myocardial infarction

Area of Science:

• Cardiology
• Pharmacology

Background:

• Thrombolytic therapy limits infarct size, improves ventricular function, and decreases mortality in evolving myocardial infarction (MI).
• Aspirin therapy also reduces mortality, stroke, and reinfarction in suspected evolving MI.

Purpose of the Study:

• To evaluate the combined efficacy of thrombolytic therapy and aspirin in managing evolving myocardial infarction.
• To assess the impact of combination therapy on reinfarction, stroke, and vascular mortality.

Main Methods:

• Review of existing studies on thrombolytic agents and aspirin in myocardial infarction.
• Comparative analysis of outcomes for monotherapy versus combination therapy.

Main Results:

• Combined thrombolytic and aspirin therapy demonstrates superior benefits compared to either agent alone.
• This combination effectively mitigates the increased reinfarction risk associated with thrombolytic therapy alone.
• Significant reductions in reinfarction, stroke, and vascular mortality were observed.

Conclusions:

• The concurrent use of aspirin with thrombolytic therapy is a crucial strategy for improving outcomes in evolving myocardial infarction.
• This approach offers enhanced protection against major adverse vascular events.